Glioma WHO-Grading II-IV C71
Conditions
Interventions
Group 1: PET/MRT of the brain in patients with glioma (WHO-Grading II-IV) after adj. radiochemotherapy
Sponsors
Radiologische Klinik, Universitätsklinikum Tübingen, Abt. Neuroradiologie
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: age: 18-80 years, histopathol.-confirmed Glioma WHO II-IV, after adj. radiochemotherapy and suspicion of a relapse (regular MRT-guided follow-up), informed consent
Exclusion criteria
Exclusion criteria: precnancy/breast feeding women, limited contractual capability, inability to lie quiescent for ca. 100 min (due to pain, claustrophobia, etc.), general contra-indication for MRT such as metallic implants, pacemaker etc., contra-indication for MR-contrast agent Gadolinium (known allergy, <60 GFR ml/min/1,73m2)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Imaging of therapy-induced effects in the parenchyma of the brain. This will be done by comparism of multiparametric data sets based on diffusion-, perfusion-, Arterial Spin Labeling (ASL)-, spectroscopy-, PET-, and conventional MRT-examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| Determination of sensitivity/specificity of PET/MRI detecting lesions, evaluation of negative/positive predictive value of different PET/MR parameters for the early detection of therapy-induced effects (pseudo-progression or pseudo-regression), The final characterization of lesions will be done either by analysis of biopsies (re-OP, 1. reference (histopathological) standard) or three sequential MRTs in nine month follow-up (2. reference (clinical) standard showing either progression or regression) and correlated to PET/MR diagnostic. | — |
Countries
Germany
Contacts
Public ContactBenjamin Bender
Radiologische Klinik, Universitätsklinikum Tübingen, Abt. Neuroradiologie
Outcome results
None listed